Literature DB >> 17120748

Effect of icariin on cyclic GMP levels and on the mRNA expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in penile cavernosum.

Zhaojian Jiang1, Benrong Hu, Jialing Wang, Qiang Tang, Yan Tan, Jizhou Xiang, Juyan Liu.   

Abstract

To further investigate the mechanisms of action of icariin (ICA), we assessed the effects of ICA on the in vitro formation of cGMP and cAMP in isolated rabbit corpus cavernosum. Isolated segments of rabbit corpus cavernosum were exposed to increasing concentrations of ICA and the dose-dependent accumulation of cGMP and cAMP was determined in the tissues samples by means of 125I radioimmunoassay. Responses of the isolated tissues preparations to ICA were compared with those obtained with the reference compounds sildenafil (Sild). Furthermore, the effects of ICA on the mRNA expression of specific cGMP-binding phosphodiesterase type V (PDE5) in rat penis were also observed. After incubation with ICA for 6 h or 14 h respectively, the levels of PDE5 mRNA were examined by reverse transcriptase polymerase chain reaction (RT-PCR). The results showed that ICA increased cGMP concentrations directly (P < 0.05), but there was no significant effect on cAMP concentrations (P > 0.05). In the presence of sodium nitroprusside (SNP), a stimulatory agent of cGMP, both ICA and Sild increased cGMP concentrations with increasing dose (P < 0.01). Their EC50 was 4.62 (ICA) and 0.42 (Sild) micromol/L respectively. Under the same condition, ICA and Sild unaltered cAMP level significantly (P > 0.05). There were PDE5A1 and PDE5A2 mRNA expressions in rat corpus cavernosum with PDE5A2 being the dominant isoform. ICA could obviously inhibit these two isoforms mRNA expression in rat penis, and decrease PDE5A1 more pronouncedly (P < 0.01). The present study indicated that the aphrodisiac mechanisms of icariin involved the NO-cGMP signal transduction pathway, with increasing cGMP levels in the corpus cavernosum smooth muscle. The inhibitory effect of icariin on PDE5 mRNA expression, especially on PDE5A1, might account for its molecular mechanisms for its long-term activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17120748     DOI: 10.1007/s11596-006-0421-y

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  10 in total

Review 1.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.

Authors:  S H Soderling; J A Beavo
Journal:  Curr Opin Cell Biol       Date:  2000-04       Impact factor: 8.382

2.  Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro.

Authors:  J Y Jeremy; S A Ballard; A M Naylor; M A Miller; G D Angelini
Journal:  Br J Urol       Date:  1997-06

Review 3.  Regulation of tone in penile cavernous smooth muscle. Established concepts and new findings.

Authors:  K E Andersson; F Holmquist
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

Review 4.  Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.

Authors:  Jackie D Corbin; Sharron H Francis; David J Webb
Journal:  Urology       Date:  2002-09       Impact factor: 2.649

5.  Cyclic GMP: synthesis, metabolism, and function. Introduction and some historical comments.

Authors:  F Murad
Journal:  Adv Pharmacol       Date:  1994

6.  Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum.

Authors:  C S Lin; A Lau; R Tu; T F Lue
Journal:  Biochem Biophys Res Commun       Date:  2000-02-16       Impact factor: 3.575

Review 7.  Cyclic nucleotide phosphodiesterases: relating structure and function.

Authors:  S H Francis; I V Turko; J D Corbin
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2001

8.  Expression of different phosphodiesterase genes in human cavernous smooth muscle.

Authors:  A Küthe; A Wiedenroth; H J Mägert; S Uckert; W G Forssmann; C G Stief; U Jonas
Journal:  J Urol       Date:  2001-01       Impact factor: 7.450

9.  Isolation of two isoforms of phosphodiesterase 5 from rat penis.

Authors:  C-S Lin; G Lin; T F Lue
Journal:  Int J Impot Res       Date:  2003-04       Impact factor: 2.896

Review 10.  Nitric oxide and cyclic GMP signaling.

Authors:  L J McDonald; F Murad
Journal:  Proc Soc Exp Biol Med       Date:  1996-01
  10 in total
  5 in total

1.  Effect of icarisid II on diabetic rats with erectile dysfunction and its potential mechanism via assessment of AGEs, autophagy, mTOR and the NO-cGMP pathway.

Authors:  Jian Zhang; Ai-Min Li; Bao-Xing Liu; Fei Han; Feng Liu; Shao-Peng Sun; Xin Li; Shu-Jin Cui; Shao-Zhong Xian; Guang-Qi Kong; Zhong-Cheng Xin; Zhi-Li Ji
Journal:  Asian J Androl       Date:  2012-06-25       Impact factor: 3.285

Review 2.  Sexual enhancement products for sale online: raising awareness of the psychoactive effects of yohimbine, maca, horny goat weed, and Ginkgo biloba.

Authors:  Ornella Corazza; Giovanni Martinotti; Rita Santacroce; Eleonora Chillemi; Massimo Di Giannantonio; Fabrizio Schifano; Selim Cellek
Journal:  Biomed Res Int       Date:  2014-06-15       Impact factor: 3.411

Review 3.  Deciphering the myth of icariin and synthetic derivatives in improving erectile function from a molecular biology perspective: a narrative review.

Authors:  Yuanjie Niu; Guiting Lin; Jiancheng Pan; Jihong Liu; Yongde Xu; Qiliang Cai; Tao Wang; Yang Luan; Yegang Chen; Yuhong Feng; Xiaoqing Yang; Wenjie Tian; Wong Jin Bae; Ruili Guan; Zhongcheng Xin
Journal:  Transl Androl Urol       Date:  2022-07

Review 4.  A review on plants used for improvement of sexual performance and virility.

Authors:  Nagendra Singh Chauhan; Vikas Sharma; V K Dixit; Mayank Thakur
Journal:  Biomed Res Int       Date:  2014-08-18       Impact factor: 3.411

5.  Role of IFT88 in icariin‑regulated maintenance of the chondrocyte phenotype.

Authors:  Wei Xiang; Jiaming Zhang; Rui Wang; Limei Wang; Shengjie Wang; Yingxing Wu; Yonghui Dong; Fengjing Guo; Tao Xu
Journal:  Mol Med Rep       Date:  2018-01-25       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.